-transparent.png){kind=logo}
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. 2008
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniromal.it
Philadelphia positive (Ph+) chronic myeloid leukaemia (CML) presenting synchronously or following non-Hodgkin lymphoma (NHL) has only rarely been reported. Herein, we refer on a case of Ph+ CML occurring after a breast cancer and a NHL with multiple relapses. After obtaining complete cytogenetic remission with imatinib, the patient presented a new NHL relapse, that was treated with rituximab concomitantly to imatinib. Therapy was well tolerated and the patient is presently alive in complete remission of either NHL and CML. We also reviewed the literature relating the uncommon association of these two unrelated diseases.
Related Publications
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
October 2010,
Leukemia research,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
August 2016,
Future oncology (London, England),
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
February 2005,
Clinical advances in hematology & oncology : H&O,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
January 2011,
Mediterranean journal of hematology and infectious diseases,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
March 2022,
Annals of translational medicine,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
December 2018,
Clinical lymphoma, myeloma & leukemia,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
February 2014,
Blood,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
April 2008,
The Lancet. Oncology,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
January 2006,
Pediatric hematology and oncology,
Massimo Breccia, and
Maurizio Martelli, and
Laura Cannella, and
Eleonora Russo, and
Erica Finolezzi, and
Caterina Stefanizzi, and
Anna Levi, and
Annamaria Frustaci, and
Giuliana Alimena
July 2003,
Lancet (London, England),
